Fitness and prostate cancer screening, incidence, and mortality: Results from the Henry Ford Exercise Testing (FIT) Project

Cancer ◽  
2021 ◽  
Author(s):  
Cara Reiter‐Brennan ◽  
Omar Dzaye ◽  
Mouaz H. Al‐Mallah ◽  
Zeina Dardari ◽  
Clinton A. Brawner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Exercise Testing ◽  
Prostate Cancer Screening ◽  
Incidence And Mortality ◽  
Henry Ford

scholarly journals Prostate Cancer Screening in African American Men: Barriers and Methods for Improvement

2008 ◽  
Vol 2 (2) ◽  
pp. 172-177 ◽  
Author(s):  
Diane Reynolds
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Cancer Screening ◽  
Access To Health Care ◽  
African American Men ◽  
Prostate Cancer Screening ◽  
Medical Profession ◽  
Inadequate Knowledge ◽  
Incidence And Mortality ◽  
Caucasian Men

African American men have the highest rate of incidence for prostate cancer in the world and are more likely to die from the disease than other ethnic groups (National Institutes of Health, 1996). Routine screening for prostate cancer can lead to early detection of the disease, thereby reducing negative outcomes, but studies have shown that African American men are less likely than Caucasian men to engage in screening practices. Lack of access to health care, socioeconomic status, inadequate knowledge, fear, patient-provider communication, distrust of the medical profession, and aversion to digital rectal exam have been identified as possible barriers to prostate cancer screening in African American men. This literature review explores causes of this striking disparity between prostate cancer incidence and mortality in African American men and cites strategies used to improve prostate cancer screening rates among this population.

Physician-Patient Discussions With African American Men About Prostate Cancer Screening

2007 ◽  
Vol 2 (2) ◽  
pp. 156-164 ◽  
Author(s):  
Louie E. Ross ◽  
Barbara D. Powe ◽  
Yhenneko J. Taylor ◽  
Daniel L. Howard
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Cancer Screening ◽  
African American Men ◽  
Prostate Cancer Screening ◽  
Specific Antigen ◽  
Psa Test ◽  
Advantages And Disadvantages ◽  
Incidence And Mortality ◽  
Physician Patient

Prostate cancer is the second leading cancer killer in men. Men in general and African American men in particular face crucial decisions regarding prostate cancer screening and perhaps treatment for this disease. Major health organizations agree that men should discuss prostate cancer screening with their physicians or other health care professionals. The purpose of the study was to examine sociodemographic and other correlates of physician-patient discussions regarding the advantages and disadvantages of the prostate-specific antigen (PSA) test among African American men aged 40 or older. A majority of African American men reported having discussed the advantages and disadvantages of prostate cancer screening and/or testing with their physicians before ordering it, and physician-patient discussions about the PSA test were associated with increased screening in African American men. Inasmuch as African American men have greater prostate cancer incidence and mortality over other groups, future attempts should be made to find meaningful correlates of PSA screening and test use to help reduce the burden of this disease.

scholarly journals A natural history model for planning prostate cancer testing: calibration and validation using Swedish registry data

2018 ◽  
Author(s):  
Andreas Karlsson ◽  
Alexandra Jauhiainen ◽  
Roman Gulati ◽  
Martin Eklund ◽  
Henrik Grönberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Natural History ◽  
Cancer Incidence ◽  
Prostate Cancer Screening ◽  
Prostate Cancer Incidence ◽  
Disease States ◽  
Natural History Model ◽  
Incidence And Mortality ◽  
The Us

AbstractRecent prostate cancer screening trials have given conflicting results and it is unclear how to reduce prostate cancer mortality while minimising overdiagnosis and overtreatment. Prostate cancer testing is a partially observable process, and planning for testing requires either extrapolation from randomised controlled trials or, more flexibly, modelling of the cancer natural history.An existing US prostate cancer natural history model (Gulati et al, Biostatistics 2010;11:707-719) did not model for differences in survival between Gleason 6 and 7 cancers and predicted too few Gleason 7 cancers for contemporary Sweden. We re-implemented and re-calibrated the US model to Sweden. We extended the model to more finely describe the disease states, their time to biopsy-detectable cancer and prostate cancer survival. We first calibrated the model to the incidence rate ratio observed in the European Randomised Study of Screening for Prostate Cancer (ERSPC) together with age-specific cancer staging observed in the Stockholm PSA (prostate-specific antigen) and Biopsy Register; we then calibrated age-specific survival by disease states under contemporary testing and treatment using the Swedish National Prostate Cancer Register.After calibration, we were able to closely match observed prostate cancer incidence trends in Sweden. Assuming that patients detected at an earlier stage by screening receive a commensurate survival improvement, we find that the calibrated model replicates the observed mortality reduction in a simulation of ERSPC.Using the resulting model, we predicted incidence and mortality following the introduction of regular testing. Compared with a model of the current testing pattern, organised 8 yearly testing for men aged 55–69 years was predicted to reduce prostate cancer incidence by 0.11% with no increase in the mortality rate. The model is open source and suitable for planning for effective prostate cancer screening into the future.Author summaryA naïve perspective is that cancer screening is simple: people are screened, some cancers are detected early, and cancer mortality rates decline. However, the mathematics for screening becomes difficult quickly, it is hard to infer causation from observational data, and even large randomised screening studies provide limited evidence. Simulations are therefore important for planning cancer screening.We found an older US prostate cancer natural history model to be poorly suited for contemporary Sweden. We therefore re-implemented and re-calibrated the US model using data from Swedish registries.Our revised model, the Stockholm “Prostata” model, provides predictions similar to those observed in the detailed Swedish registers on prostate cancer incidence and mortality. By modelling the mechanisms of the screening effect, we can predict the benefits and harms under a range of screening interventions.

1035: Prevalence of Erectile Dysfunction in a Prostate Cancer Screening Population

2007 ◽  
Vol 177 (4S) ◽  
pp. 342-342
Author(s):  
Jochen Walz ◽  
Georg Salomon ◽  
Paul Perrotte ◽  
Andrea Gallina ◽  
Georg C. Hutterer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Erectile Dysfunction ◽  
Cancer Screening ◽  
Prostate Cancer Screening ◽  
Screening Population

1462: The use of an Upper age Limit in Prostate Cancer Screening

2005 ◽  
Vol 173 (4S) ◽  
pp. 396-396
Author(s):  
Monique J. Roobol ◽  
Claartje Gosselaar ◽  
Fritz H. Schröder
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Prostate Cancer Screening ◽  
Age Limit

435: When is Decreased Prostate Cancer Mortality to be Expected Provided that Efficacious Prostate Cancer Screening is Introduced?

2004 ◽  
Vol 171 (4S) ◽  
pp. 115-115
Author(s):  
Magnus Törnblom ◽  
Henry Eriksson ◽  
Stefan Franzen ◽  
Ove Gustafsson ◽  
Hans Lilja ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Cancer Mortality ◽  
Prostate Cancer Screening ◽  
Prostate Cancer Mortality
Sign in / Sign up

Export Citation Format

Share Document